Phase 2 Atrial Fibrillation Trial, Recruiting NCT06279793 Sponsor: GCP-Service International West GmbH Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 2 Atrial Fibrillation Trial, Recruiting

NCT06279793
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing and able to sign a consent form before the study begins
  • You must be 18 years old or older
  • You must be scheduled for planned (non-emergency) heart surgery using a heart-lung bypass machine, and your surgery must be one of the following types: heart valve surgery, coronary artery bypass surgery (CABG), a combination of valve and bypass surgery, multiple valve surgeries, other combined heart procedures, or surgery on the aorta (the main artery from the heart)
  • In addition to the surgery type, you must also have at least one of the following risk factors: a predicted surgical risk of death of 8% or higher (based on a scoring tool called EuroSCORE II), be aged 70 or older, have a frailty score of 4 or above on a standard frailty scale, need surgery urgently within 24–48 hours of being admitted to hospital, or have a weakened heart that pumps less than 35% of its normal capacity

Who may not be able to join:

  • You have a known allergy to fish, fish oil, or egg protein
  • You are pregnant or currently breastfeeding
  • You have a history of long-term irregular heart rhythms such as atrial fibrillation, atrial flutter, or related conditions
  • You are unwilling or unable to sign a consent form
  • You are not expected to survive more than 48 hours from the time of assessment
  • There are plans to limit or withdraw your medical treatment within the first week (though a "do not resuscitate" order alone does not exclude you)
  • You have been admitted with a serious diabetic crisis (such as diabetic ketoacidosis or a related condition)
  • You are currently using a mechanical heart support device or receiving advanced heart failure treatments
  • You have taken part in another interventional clinical trial within the last 30 days
  • You are already receiving medical nutrition products that contain fish oil
  • You are severely underweight, with a body mass index (BMI) below 18.5
  • You have severe liver disease (classified as Child Pugh Class C) (confirm with trial site)
  • You have severe long-term kidney disease, with kidney function measured at less than 30 ml/min
  • You have a known severe disorder affecting your blood's ability to clot

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Christian Stoppe, Prof. Dr., Wuerzburg University Hospital

Phone: 49-931-20130001

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
GCP-Service International West GmbH
Registry
ClinicalTrials.gov
Start date
15 February 2024
Est. completion
1 March 2030

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Atrial fibrillation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov